JPMorgan lowered the firm’s price target on Immunovant (IMVT) to $37 from $40 and keeps an Overweight rating on the shares. The firm updated the company’s model post earnings.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMVT:
- Immunovant’s Promising Pipeline and Strong Financial Position Signal a Buy Rating
- Immunovant’s Promising Advances in Graves’ Disease Treatment Drive Buy Rating
- Immunovant Reports Progress and Financial Results
- Immunovant’s Strategic Advancements and Clinical Progress Justify Buy Rating
- Immunovant price target lowered to $57 from $58 at Citi